Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.55 |
| ▸ | STAT3 | P40763 | 2/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30078825 | 1.00 | TYK2 (0.55) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30078887 | 0.89 | TYK2 (0.56) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30079090 | 0.89 | TYK2 (0.69) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30078995 | 0.89 | TYK2 (0.68) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30079058 | 0.88 | TYK2 (0.61) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL23779217 | 0.85 | TYK2 (0.53) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30079676 | 0.85 | TYK2 (0.53) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30079133 | 0.85 | TYK2 (0.61) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30079027 | 0.84 | TYK2 (0.67) | TYK2STAT3JAK2JAK1STAT1 | |
| SCHEMBL30227331 | 0.84 | TYK2 (0.73) | TYK2STAT3JAK2JAK1STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873892-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | Bristol-Myers Squibb Company (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113227071-A | Amide-substituted heterocyclic compounds for the treatment of disorders associated with the modulation of IL-12, IL-23 and/or IFN-alpha | 百时美施贵宝公司 | 2021-08-06 | — | — | CN | disclosed |